Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report.
We report the case of a 26-year-old man in whom glioblastoma multiforme had recurred six months following a subtotal resection. Despite radiotherapy and a course of interferon beta and ACNU, the tumour increased in size (to 3 cm) and there was neurological deterioration. Treatment was then initiated with LAK cells, together with ACNU and interferon beta. After three courses of LAK cells, tumour size was markedly reduced, and at about six months the tumour had nearly disappeared on computed tomographic (CT) scans. At one year, and after nine courses of LAK cell therapy (total dose of 2.7 x 10(9) cells) infused via an Ommaya reservoir and supplemented by ACNU and interferon beta, the tumour has disappeared and the patient is considered to be in complete remission since 6 months. This marked response is thought to be due chiefly to LAK cell therapy. The relatively low dose administered was well-tolerated.
Naganuma
H
H
Department of Neurosurgery, Yamanashi Medical College, Japan.
Kimurat
R
R
Sasaki
A
A
Fukamachi
A
A
Nukui
H
H
Tasaka
K
K
D000328:Adult; D001932:Brain Neoplasms / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005625:Frontal Lobe / Q000601:surgery; D005909:Glioblastoma / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007370:Interferon Type I / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007694:Killer Cells, Natural / Q000637:transplantation; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D015376:Nimustine / Q000008:administration & dosage; D010296:Parietal Lobe / Q000601:surgery; D011183:Postoperative Complications / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage
D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins; D015376:Nimustine